FDA
-
-
-
-
-
-
-
Pipeline and capital for growth
-
-
-
-
-
-
-
Pre-Open Stock Movers 08/19: (MNTA) (HUD) (IMVT) Higher; (BMRN) (GLPG) (VIPS) Lower (more...)
-
-
-
-
-
-
-
NEW ANALYSES OF PHASE 2 EQUATOR CLINICAL PROGRAM SUPPORT DURABLE EFFICACY OF FILGOTINIB IN PSORIATIC ARTHRITIS
-
-
-
-
-
-
-
NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE
-
-
-
-
-
-
-
GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS
-
-
-
-
-
-
-
Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
-
-
-
-
-
-
-
Galapagos NV (GLPG) Announces Fast Track Designation from FDA for GLPG1972/S201086 in Osteoarthritis
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

